Eli Lilly And Company (LLY) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

Company Performance - Lilly reported a strong second quarter performance, driven primarily by the incretins Mounjaro and Zepbound, with Mounjaro showing significant sales outside the U.S. [2] - The company anticipates several product launches across various disease areas in the second half of the year, indicating a robust pipeline for the remainder of the decade [3] Management Insights - The management team, including Patrik Jonsson and Mike Czapar, expressed confidence in the company's performance and future growth prospects [1][2]